Summary
The main aim of sedation in the critically ill patient is to provide relief from anxiety and pain. The current, ideal level of sedation should leave a patient who is lightly asleep but easily roused. No single regimen is suitable for all patients. The level of sedation should be monitored, and the choice of agent, the dose and the route of administration adjusted appropriately.
Midazolam is often used to provide sleep and anxiolysis. Alternatives include propofol and isoflurane. Propofol is easily titrated to achieve the desired level of sedation, and its effects rapidly end when the infusion is stopped. Isoflurane also appears promising, but special equipment is needed for its administration. Morphine is the standard analgesic agent. The principal metabolites, morphine-6-glucuronide, is also a potent opioid agonist and may accumulate in renal failure. Of the newer analgesic agents, alfentanil is an ideal agent for infusion, and may be the agent of choice in renal failure. Neuromuscular blocking agents are indicated only in specific circumstances, and used only once it is known patients are asleep and pain free.
The actions of these agents are unpredictable in the critically ill patient. Alterations in drug effect and elimination may occur, especially in the patient with hepatic and renal failure. This may also apply to active metabolites of the parent drug.
When planning sedation regimens, specific patient needs and staffing levels must be remembered. Attention to the environment is also important. Midazolam and morphine given by intermittent bolus or by infusion are the mainstay of most regimens. Propofol is ideal for short periods of care on the ICU, and during weaning when longer acting agents are being eliminated.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adam K, Oswald I. Sleep helps healing. British Medical Journal 289: 1400–1401, 1984
Aitkenhead AR, Pepperman ML, Willatts SM, Coates PD, Park GR, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 2: 704–709, 1989
Aurell J, Elmqvist D. Sleep in the surgical intensive care unit: continuous polygraphic recording of sleep in nine patients receiving postoperative care. British Medical Journal 290P: 1029–1032, 1985
Bellantuono C, Reggi V, Tognoni G, Garattini S. Benzodiazepines: clinical pharmacology and therapeutic use. Drugs 19: 195–219, 1980
Bion JF, Ledingham I McA. Sedation in the intensive care — a postal survey. Correspondence. Intensive Care Medicine 13: 215–216, 1987
Bodenham A, Brownlie G, Dixon JS, Park GR. Reversal of sedation by prolonged infusion of flumazenil (Anexate Ro 15-1788). Anaesthesia 43: 376–378, 1988
Bodenham A, Park GR. Alfentanil infusions in patients requiring intensive care. Clinical Pharmacokinetics 15: 216–226, 1988
Bodenham A, Quinn K, Park GR. Extrahepatic metabolism of morphine. British Journal of Anaesthesia 63: 380–384, 1989
Bodenham A, Park GR. Plasma concentrations of bupivacaine after intercostal nerve block in patients after orthotopic liver transplanation. British Journal of Anaesthesia 64: 436–441, 1990
Brogden RN, Goa KL. Flumazenil: a preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use. Drugs 35: 448–467, 1988
Bronheim HE, Iberti TJ, Benjamin E, Strain JJ. Depression in the intensive care unit. Critical Care Medicine 13: 985–988, 1985
Burgess P, Hall RI, Bateman DN, Johnston IDA. The effect of total parenteral nutrition on hepatic drug oxidation. Journal of Parenteral and Enterai Nutrition 11: 540–543, 1987
Carrupt P-A, Testa B, Bechalany A, El Tayar N, Descas P, et al. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. Journal of Medicinal Chemistry 34: 1272–1275, 1991
Chiolero RL, Ravussin P, Anderes JP, Ledermann P, de Tribolet N. The effects of midazolam reversal with Ro 15-1788 on cerebral perfusion pressure in patients with severe head injury. Intensive Care Medicine 14: 196–200, 1988
Clive DM, Stoff JS. Renal syndromes associated with non-steroidal antiinflammatory drugs. New England Journal of Medicine 310: 563–572, 1984
Committee on Safety of Medicines. Genotoxicity of papaveretum and noscapine. Current Problems 30: june, 1991
Dahl JB, Kehlet H. Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. British Journal of Anaesthesia 66: 703–712, 1991
Dundee JW, Johnston HML, Gray RC. Lorazepam as a sedative-amnesic in an intensive care unit. Current Medical Research and Opinion 4: 290–295, 1976
Ferenci P, Pappas SC, Munson PJ, Henson K, Jones EA. Changes in the status of neurotransmitter receptors in a rabbit model of hepatic encephalopathy. Hepatology 4: 186–191, 1984
Ferner C, Marty J, Bouffard Y, Haberer JP, Levron JC, et al. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 62: 480–484, 1985
Gatehouse DG, Stemp G, Pascoe S, Wilcox P, Hawker J, et al. Investigation into the induction of aneuploidy and polyploidy in mammalian cells by the anti-tussive agent noscapine hydrochloride. Mutagenesis 6: 279–283, 1991
Gray PA, Park GR. Chlormethiazole sedation for critically ill patients in renal failure. Anaesthesia 44: 913–915, 1989
Green D. Paralysis or sedation for controlled ventilation. Lancet 1: 715, 1980
Hill SA, Quinn K, Shelly MP, Park GR. Reversible renal failure following opioid administration. Anaesthesia 46: 938–939, 1991
Kong KL, Willatts SM, Prys-Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unit. British Medical Journal 298: 1277–1279, 1989
Kornfeld DS, Zimberg S, Malm JR. Psychiatric complications of open heart surgery. New England Journal of Medicine 273: 287–292, 1965
Langley MS, Heel RC. Propofol: a review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic. Drugs 35: 334–372, 1988
Lassen HCA, Bjorneboe M, Ibsen B, Neukirch F. Treatment of tetanus with curarisation, general anaesthesia and intratracheal positive pressure ventilation. Lancet 2: 1040–1044, 1954
Lassen HCA, Henriksen E, Neurkirch F, Kristensen HS. Treatment of tetanus severe prolonged bone-marrow depression after prolonged nitrous oxide anaesthesia. Lancet 1: 527–530, 1956
Lazarus HR, Hagens JH. Prevention of psychosis following open-heart surgery. American Journal of Psychiatry 124: 1190–1195, 1968
Manara AR, Bodenham AR, Park GR. Analgesic efficacy of perioperative buccal morphine. British Journal of Anaesthesia 64: 551–555, 1990
Mandelli M, Tognoni G, Garattini S. Clinical Pharmacokinetics of diazepam. Clinical Pharmacokinetics 3: 72–91, 1978
Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clinical Pharmacokinetics 8: 422–446, 1983
Mazze RI, Cousins MJ, Barr GA. Renal effects and metabolism of isoflurane in man. Anesthesiology 40: 536–542, 1974
McQuay HJ, Bullingham RES, Moore RA. Acute opiate tolerance in man. Life Sciences 28: 2513–2517, 1981
Merriman HM. The techniques used to sedate ventilated patients. Intensive Care Medicine 7: 217–224, 1981
Modig J. Indications of chlormethiazole as a protective agent in experimental endotoxaemia. European Surgical Research 20: 195–204, 1988
Moudgil GC. Effect of premedicants, intracenous anaesthetic agents and local anaesthetics on phagocytosis in vitro. Canadian Anaesthetists’ Society Journal 28: 597–601, 1981
Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. British Medical Journal 292: 1548–1549, 1986
O’Sullivan G, Park GR. The assessment of sedation. Journal of Clinical Intensive Care 1: 116–121, 1990
Park GR, Burns AM. Isoflurane compared with midazolam in the intensive care unit. British Medical Journal 298: 1642, 1989
Park GR, Manara AR, Dawling S. Extra-hepatic metabolism of midazolam. British Journal of Clinical Pharmacology 27: 634–637, 1989
Park GR, Gray PA. Infusions of analgesics, sedatives and muscle relaxants in patients who require intensive care. Anaesthesia 44: 879–880, 1989
Parker CJR, Jones JE, Hunter JM. Dispositions of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. British Journal of Anaesthesia 61: 531–540, 1988
Scott DB, Beamish D, Hudson IN, Jostell KG. Prolonged infusion of chlormethiazole in intensive care. British Journal of Anaesthesia 52: 541–545, 1980
Shelly MP, Park GR, Mendel L. Failure of critically ill patients to metabolise midazolam. Anaesthesia 42: 619–626, 1987
Shelly MP, Roberts P, Quinn K, Park GR. Dihydrocodeine: a cause of renal failure. European Journal of Anaesthesiology 6: 303–314, 1989
Shelly MP, Sultan MA, Bodenham A, Park GR. Midazolam infusions in critically ill patients. European Journal of Anaesthesiology 8: 21–27, 1991
Shimomura K, Kamata O, Ueki S, Ida S, Oguri K, et al. Analgesic effect of morphine glucuronides. Tohoku Journal of Experimental Medicine 105: 45–52, 1971
Sladen RN, Jenkins LC. Intermittent mandatory ventilation and controlled mechanical ventilation without positive end-expiratory pressure following cardiopulmonary bypass. Canadian Anaesthetists’ Society Journal 25: 166–172, 1978
Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Annals of Internal Medicine 86: 738–741, 1977
Truog RD, Rice SA. Inorganic fluoride and prolonged isoflurane anaesthesia in the intensive care unit. Anesthesia and Analgesia 69: 843–845, 1989
Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C. Effects of morphine on resistance to infection. Journal of Infectious Diseases 148: 656–666, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burns, A.M., Shelly, M.P. & Park, G.R. The Use of Sedative Agents in Critically Ill Patients. Drugs 43, 507–515 (1992). https://doi.org/10.2165/00003495-199243040-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199243040-00007